[Source: TGen] – Life Technologies Corporation (NASDAQ: LIFE) today announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.
The goal of this first-of-its-kind research collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals.
While genomic sequencing has made great strides in helping researchers understand human disease, its clinical utility is not fully known. This research study brings together the accuracy of the Applied Biosystems SOLiD™ System, with US Oncology’s expertise in cancer trials and TGen’s Cancer Genome and Oncology programs, to provide additional information for oncologists and their patients. Triple negative tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with common targeted breast cancer therapies such as Herceptin.